Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

EXPLAINED: Immunitybio - The Real Truth

FDA Expands Anktiva Approval to Papillary-Only Bladder Cancer That Resists BCG, Giving Patients a Nonsurgical Option

The FDA expanded Anktiva plus BCG to papillary-only bladder cancer that no longer responds to BCG. Here is who qualifies, what the data show, and what remains uncertain.

Medical Daily · Oct 15

FDA flags misleading claims for cancer drug by biotech billionaire Patrick Soon-Shiong

Federal health officials have issued a warning about controversial statements made by biotech billionaire Dr. Patrick Soon-Shiong about one of his company's cancer drugs

The Independent UK · Mar 24

Why 2 Small Biotechs May Hold the Key to New Cancer Treatments

Iovance and ImmunityBio have doubled and quadrupled in share price so far this year, respectively, thanks to powerful cancer medicines that could upend care.

MarketBeat · Mar 12

From analysis to the latest developments in health,
read the most diverse news in one place.

Small Caps Can Only Lead Stocks So High: Stock Market Today

The main U.S. equity indexes were down for the week, but small-cap stocks look as healthy as they ever have.

Kiplinger · Jan 16

Biotech Breakouts: 3 Stocks With Massive Upside Potential

Biotech stocks are highly volatile; however, these biotech stocks have key trial results this fall that could spark sharp moves and long-term growth potential

MarketBeat · Sep 17, 2025

What's Going On With ImmunityBio Shares Tuesday?

ImmunityBio, Inc. (NASDAQ:IBRX) shares are trading higher Tuesday after the company announced its chemotherapy-free combination showed 100% disease control results and is planning a Phase 2 trial.

Benzinga · Aug 26, 2025

Benzinga's Top Ratings Upgrades, Downgrades For August 3, 2022

Benzinga · Aug 3, 2022

Read news from The Economist, FT, and more,
with one subscription

Billionaire Soon-Shiong bets Africa is cure for flatlined stock

At this time a year ago, investors saw billionaire Patrick Soon-Shiong’s biotech company ImmunityBio Inc. as a moonshot that would make them rich.

Tribune News Service · Feb 22, 2022

The Daily Biotech Pulse: Larimar Plunges On Extension Of Clinical Hold, ImmunityBio Gains On Positive Data, Adcom Test Awaits Avenue Therapeutics

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga · Feb 15, 2022

The Daily Biotech Pulse: ImmunityBio Reports Positive Readout, Valneva Starts Late-Stage Chikungunya Vaccine Study, Sio Gene Shelves Parkinson's Program

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga · Feb 1, 2022

ImmunityBio's Shares Jump On Encouraging Data From Pancreatic Cancer Immunotherapy Trial

ImmunityBio Inc (NASDAQ: IBRX) has

Benzinga · Jan 19, 2022

The Daily Biotech Pulse: Gamida Gains On Positive Regulatory Development, Orphazyme & ADMA Preannouncements, ImmunityBio & Leap Present Positive Data

Here's a roundup of top developments in the biotech space over the last 24 hours.

Benzinga · Jan 19, 2022

Coverage From

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.